Migraine as an inflammatory disorder
暂无分享,去创建一个
[1] H. Chabriat,et al. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. , 2004, Archives of neurology.
[2] M. Møller,et al. Origin of PACAP-immunoreactive Nerve Fibers Innervating the Subarachnoidal Blood Vessels of the Rat Brain , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] J. Olesen,et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. , 2004, The New England journal of medicine.
[4] R. Ravid,et al. EP4 prostanoid receptor‐mediated vasodilatation of human middle cerebral arteries , 2004, British journal of pharmacology.
[5] R. Burstein,et al. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization , 2004, Annals of neurology.
[6] W. Willis,et al. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin , 2003, Pain.
[7] K. Welch. Stroke and migraine--the spectrum of cause and effect. , 2003, Functional neurology.
[8] H. Diener. Rpr100893, A Substance-P Antagonist, is Not Effective in the Treatment of Migraine Attacks , 2003, Cephalalgia : an international journal of headache.
[9] M. Moskowitz,et al. Nuclear factor-kappaB as a molecular target for migraine therapy. , 2003, Annals of neurology.
[10] L. May,et al. Efficacy and Safety of Acetaminophen and Naproxen in the Treatment of Tension-Type Headache. A Randomized, Double-Blind, Placebo-Controlled Trial , 2002, Cephalalgia : an international journal of headache.
[11] Y. Sugimoto,et al. Prostanoid receptor subtypes. , 2002, Prostaglandins & other lipid mediators.
[12] M. Weber,et al. Efficacy of oral ketoprofen in acute migraine: A double-blind randomized clinical trial , 2002, Neurology.
[13] M. Boehme,et al. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects , 2002, Rheumatology International.
[14] J. Olesen,et al. Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.
[15] Andrew K. Dunn,et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model , 2002, Nature Medicine.
[16] M. Moskowitz,et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. , 2001, Brain : a journal of neurology.
[17] W. Feniuk,et al. Characterization of the prostanoid receptor types involved in mediating calcitonin gene‐related peptide release from cultured rat trigeminal neurones , 2001, British journal of pharmacology.
[18] R. Couture,et al. Kinin receptors in pain and inflammation. , 2001, European journal of pharmacology.
[19] L. Edvinsson. Sensory Nerves in Man and Their Role in Primary Headaches , 2001, Cephalalgia : an international journal of headache.
[20] E. Nelson,et al. Efficacy of Nonprescription Doses of Ibuprofen for Treating Migraine Headache. A Randomized Controlled Trial , 2001, Headache.
[21] Q. Ma,et al. Co-localization of 5-HT1B/1D/1F receptors and glutamate in trigeminal ganglia in rats , 2001, Neuroreport.
[22] J. Korf,et al. Migraine and Function of the Immune System: A Meta-Analysis of Clinical Literature Published Between 1966 and 1999 , 2001, Cephalalgia : an international journal of headache.
[23] Q. Ma,et al. Colocalization of CGRP with 5‐HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats , 2001, The European journal of neuroscience.
[24] R. Hargreaves,et al. Neurogenic inflammation in the context of migraine , 2001, Microscopy research and technique.
[25] R. Burstein,et al. Deconstructing migraine headache into peripheral and central sensitization , 2001, Pain.
[26] A. Rizzi,et al. Classification of Kinin Receptors , 2001, Biological chemistry.
[27] D. Čížková,et al. The role of nitric oxide in nociception , 2000, Current review of pain.
[28] V. Gallai†,et al. Nitric Oxide Metabolites, Prostaglandins and Trigeminal Vasoactive Peptides in Internal Jugular Vein Blood During Spontaneous Migraine Attacks , 2000, Cephalalgia : an international journal of headache.
[29] S. Bingham,et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia , 2000, Nature.
[30] R. Lipton,et al. Evaluation of a Novel Solubilized Formulation of Ibuprofen in the Treatment of Migraine Headache: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study , 2000, Cephalalgia : an international journal of headache.
[31] D. Julius,et al. Capsaicin receptor in the pain pathway. , 2000, Japanese journal of pharmacology.
[32] A I Basbaum,et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. , 2000, Science.
[33] E. Hamel,et al. No contractile effect for 5‐HT1D and 5‐HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery , 2000, British journal of pharmacology.
[34] A. A. Parsons,et al. Effects of sumatriptan on nitric oxide and superoxide balance during glyceryl trinitrate infusion in the rat. Implications for antimigraine mechanisms , 1999, Brain Research.
[35] H. Diener. Efficacy and Safety of Intravenous Acetylsalicylic Acid Lysinate Compared To Subcutaneous Sumatriptan and Parenteral Placebo in the Acute Treatment of Migraine. A Double-Blind, Double-Dummy, Randomized, Multicenter, Parallel Group Study , 1999 .
[36] H. Handwerker,et al. Nociceptive neurons in the rat caudal trigeminal nucleus respond to blood plasma perfusion of the subarachnoid space: the involvement of complement , 1999, Pain.
[37] K. Messlinger,et al. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro , 1999, Neuroscience.
[38] Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater , 1999, Neuroscience Letters.
[39] H. Diener. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. , 1999, Cephalalgia : an international journal of headache.
[40] R. Egan,et al. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.
[41] C. Waeber. The Role of 5-HT1B/1D Receptors in the Treatment of Migraine , 1998, CNS Spectrums.
[42] S. Moore,et al. Regulation of prostaglandin H synthase‐2 expression in cerebromicrovascular smooth muscle by serum and epidermal growth factor , 1998, Journal of cellular physiology.
[43] A. Basbaum,et al. The Cloned Capsaicin Receptor Integrates Multiple Pain-Producing Stimuli , 1998, Neuron.
[44] A. Rizzi,et al. Bradykinin receptors and their antagonists. , 1998, European journal of pharmacology.
[45] P. Bonaventure,et al. 5HT1B and 5HT1D receptor mRNA differential co‐localization with peptide mRNA in the guinea pig trigeminal ganglion , 1998, Neuroreport.
[46] R. Burstein,et al. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. , 1998, Journal of neurophysiology.
[47] J. Olesen,et al. Nitric Oxide Synthase Inhibition: A New Principle in the Treatment of Migraine Attacks , 1998, Cephalalgia : an international journal of headache.
[48] J. Saper,et al. Ineffectiveness of Neurokinin-1 Antagonist in Acute Migraine , 1997, Cephalalgia : an international journal of headache.
[49] R. Hargreaves,et al. Sumatriptan Inhibits Neurogenic Vasodilation of Dural Blood Vessels in the Anaesthetized Rat—Intravital Microscope Studies , 1997, Cephalalgia : an international journal of headache.
[50] C. Woolf,et al. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α , 1997, British journal of pharmacology.
[51] L. Phebus,et al. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. , 1997, Life sciences.
[52] M. Perren,et al. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system , 1997, Regulatory Peptides.
[53] M. Hildebrand. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients , 1997, European Journal of Clinical Pharmacology.
[54] R. Burstein,et al. Sensitization of meningeal sensory neurons and the origin of headaches , 1996, Nature.
[55] P. Séguéla,et al. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. , 1996, Molecular pharmacology.
[56] C. Tassorelli,et al. NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration , 1995, Brain Research.
[57] M. T. Brewer,et al. Mechanisms of tumor necrosis factor-α (TNF-α) hyperalgesia , 1995, Brain Research.
[58] S. Brain,et al. The modulation of the increase in rat facial skin blood flow observed after trigeminal ganglion stimulation. , 1995, European journal of pharmacology.
[59] C. Woolf,et al. Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia , 1995, British journal of pharmacology.
[60] S. McMahon,et al. Immunocytochemical Localization of trkA Receptors in Chemically Identified Subgroups of Adult Rat Sensory Neurons , 1995, The European journal of neuroscience.
[61] A. Dray,et al. Kinins and kinin receptors in the nervous system , 1995, Neurochemistry International.
[62] S. Brain,et al. Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide , 1995, Brain Research.
[63] M. T. Brewer,et al. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. , 1995, Brain research.
[64] F. Sundler,et al. Pituitary adenylate cyclase activating polypeptide expression in sensory neurons , 1994, Neuroscience.
[65] P. Goadsby,et al. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. , 1994, Journal of the autonomic nervous system.
[66] M. Perkins,et al. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine‐induced mechanical hyperalgesia in the rat , 1994, British journal of pharmacology.
[67] S. Maier,et al. Characterization of cytokine-induced hyperalgesia , 1994, Brain Research.
[68] M. Moskowitz,et al. Blockade by oral or parenteral RPR 100893 (a non‐peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea‐pig dura mater and conjunctiva , 1994, British journal of pharmacology.
[69] S. Narumiya,et al. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. , 1994, Pharmacological reviews.
[70] D. Haas. Migraine and Intracranial Vascular Malformations , 1994, Headache.
[71] H. Holthusen,et al. Nitric oxide evokes pain in humans on intracutaneous injection , 1994, Neuroscience Letters.
[72] S. Ferreira,et al. Bradykinin initiates cytokine‐mediated inflammatory hyperalgesia , 1993, British journal of pharmacology.
[73] G. Jonakait. Neural—immune interactions in sympathetic ganglia , 1993, Trends in Neurosciences.
[74] J. Olesen,et al. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. , 1993, Neuroreport.
[75] P. Goadsby,et al. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.
[76] M. Moskowitz,et al. Neurovascular and molecular mechanisms in migraine headaches. , 1993, Cerebrovascular and brain metabolism reviews.
[77] Z. Huang,et al. UK-14,304, R(-)-alpha-methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. , 1992, European journal of pharmacology.
[78] M. Moskowitz,et al. Calcitonin gene-related peptide mediates nitroglycerin and sodium nitroprusside-induced vasodilation in feline cerebral arterioles. , 1992, Circulation research.
[79] J. Olesen,et al. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: Comparison with cerebral and temporal arteries , 1992, Peptides.
[80] M. Moskowitz,et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation , 1992, Neuroscience.
[81] A. Denman. Cellular and Molecular Immunology , 1992 .
[82] M. Ferrari,et al. Blood Flow Velocities in the Vertebrobasilar System During Migraine Attacks a Transcranial Doppler Study , 1992, Cephalalgia : an international journal of headache.
[83] M. Moskowitz. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. , 1992, Trends in pharmacological sciences.
[84] F. Cunha,et al. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. , 1992, British journal of pharmacology.
[85] M. Moskowitz,et al. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells , 1991, Neuroscience.
[86] P. Goadsby,et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache , 1990, Annals of neurology.
[87] P. Barnes,et al. Modulation of neurogenic inflammation: novel approaches to inflammatory disease. , 1990, Trends in pharmacological sciences.
[88] E. Whalley,et al. Cerebrovascular effects of prostanoids: in-vitro studies in feline middle cerebral and basilar artery. , 1989, Prostaglandins.
[89] A. A. Parsons,et al. Effects of Prostanoids on Human and Rabbit Basilar Arteries Precontracted In Vitro , 1989, Cephalalgia : an international journal of headache.
[90] J. O. Tuca,et al. Increase in PGE2 and TXA2 in the Saliva of Common Migraine Patients. Action of Calcium Channel Blockers , 1989, Headache.
[91] R. Coggeshall,et al. Peptide immunoreactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[92] M. Massobrio,et al. Relevance of Prostaglandins in True Menstrual Migraine , 1989, Headache.
[93] M. Moskowitz,et al. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches , 1988, Annals of neurology.
[94] S. Ferreira,et al. Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogue , 1988, Nature.
[95] K. Hongo,et al. Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries. , 1988, Journal of neurosurgery.
[96] J. Olesen,et al. Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. , 1988, Archives of neurology.
[97] P. Goadsby,et al. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system , 1988, Annals of neurology.
[98] M. Moskowitz,et al. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[99] I. Kanazawa,et al. Regional distribution of substance P, neurokinin α and neurokinin β in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection , 1985, Brain Research.
[100] P. Emson,et al. Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis , 1985, Brain Research.
[101] R. Peatfield,et al. The Effect of Infused Prostacyclin in Migraine and Cluster Headache , 1981, Headache.
[102] E. Melamed,et al. NEUROTRANSMITTERS AND THE FIFTH CRANIAL NERVE: IS THERE A RELATION TO THE HEADACHE PHASE OF MIGRAINE? , 1979, The Lancet.
[103] J. Charlesworth,et al. COMPLEMENT ACTIVATION IN MIGRAINE , 1977, The Lancet.
[104] L. Ekelund,et al. Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. , 2009, Acta medica Scandinavica.
[105] H. Wolff,et al. MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE , 1938 .